This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combinedquercetin/curcumin supplement in adults experiencing mild to moderate symptoms of LongCOVID-19. Participants will receive the combined quercetin/curcumin supplement for 2months. The primary outcome is the improvement in overall symptom burden, while secondaryoutcomes include changes in quality of life, the need for NSAIDs, and inflammatorymarkers. The study seeks to provide real-world evidence of the potential benefits of thiscombined supplement in managing Long COVID-19 symptoms.
Long COVID-19, characterized by persistent symptoms lasting weeks or months after the
acute phase of SARS-CoV-2 infection, presents a significant challenge for healthcare
systems and affected individuals. Common symptoms include fatigue, brain fog, muscle
pain, joint pain, sleep disturbances, and generalized weakness. Despite extensive
research, there are limited effective therapeutic options for managing Long COVID-19
symptoms.
Quercetin and curcumin, two natural compounds with well-documented anti-inflammatory,
antioxidant, and immunomodulatory properties, have gained attention for their potential
benefits in various inflammatory and infectious conditions. Quercetin, a flavonoid found
in various fruits and vegetables, has been shown to inhibit pro-inflammatory cytokines,
reduce oxidative stress, and modulate immune responses. Curcumin, a polyphenol derived
from turmeric (Curcuma longa), is known for its strong anti-inflammatory and antioxidant
properties and has demonstrated immune-modulating effects in clinical studies.
Nasafytol® is a standardized combination supplement containing bioactive quercetin (65
mg) and curcumin (42 mg) from Curcuma longa, specifically formulated to enhance
bioavailability and provide synergistic benefits. Both quercetin and curcumin in
Nasafytol® are optimized for absorption and efficacy, making it a promising intervention
for managing inflammatory and immune-related conditions.
The combination of quercetin and curcumin in Nasafytol® is hypothesized to provide
synergistic benefits in managing Long COVID-19 symptoms. This pragmatic clinical study
aims to evaluate the efficacy of Nasafytol® in reducing symptom burden and improving
quality of life in adults experiencing mild to moderate Long COVID-19 symptoms.
Participants will receive the combined supplement for two months, with primary outcomes
focused on symptom improvement and secondary outcomes assessing changes in quality of
life, the need for NSAIDs, and inflammatory markers.
The study is designed as a real-world pragmatic trial to provide evidence of the
potential health benefits of Nasafytol® for Long COVID-19, addressing a critical gap in
current management strategies.
Dietary Supplement: Nasafytol® (Quercetin/Curcumin Supplement)
Participants in this group will receive Nasafytol®, a combined dietary supplement
containing quercetin (65 mg) and curcumin (42 mg). Participants will take two capsules
(single administration) twice a day for a duration of 8 weeks. The supplement is intended
to alleviate mild to moderate symptoms of Long COVID-19, including but not limited to
fatigue, cognitive function, generalized body pain, low mood, sleep disturbance, and
overall quality of life.
Inclusion Criteria:
- Age: 18 to 75 years.
- History of confirmed COVID-19 infection at least 6 months prior to the enrollment.
- Persistent mild to moderate COVID-19 symptoms for at least 3 months post-acute
infection.
- Diagnosis of Long COVID-19 based on WHO criteria.
- Symptom burden score of ≥25 at baseline (V0) on the COVID-19 Yorkshire
Rehabilitation Scale (C19-YRS).
- At least one symptom scoring between 1-7 on the C19-YRS.
- Stable medical condition: No recent hospitalization (past 3 months) due to acute
illness.
- Willing and able to adhere to the study protocol, including follow-up visits,
symptom reporting, and compliance with supplementation
Exclusion Criteria:
- Hypersensitivity or allergy to quercetin, curcumin, or any component of the
supplement (Nasafytol®).
- Severe, uncontrolled chronic illness (e.g., severe heart failure, chronic kidney
disease requiring dialysis, severe liver disease).
- Regular use of quercetin or curcumin supplements within the last 3 months.
- Use of anticoagulants (e.g., warfarin, heparin, DOACs) due to potential
anticoagulant effects of quercetin/curcumin.
- Acute illness at the time of screening.
- Pregnancy or breastfeeding.
- Use of immunosuppressive medications or corticosteroids within the past month.
- Significant psychiatric disorder that may interfere with study compliance.
Liaquat University of Medical & Health Sciences (LUMHS)
Jamshoro, Sindh, Pakistan
Investigator: Dr. Amjad Khan, DPhil
amjadkhan@lumhs.edu.pk
Not Provided